RET and medullary thyroid gland carcinoma: Targeted drugs are recommended for patients with DM, particularly because studies have demonstrated [11, 21] that RET-specific inhibitors (selpercatinib and pralsetinib) are effective and promising therapies for MTC patients with DM and progression.